In today's edition of the Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss Stryker's surprise buyout of robotic surgical specialist MAKO Surgical, as well as other market movers in the biotech space.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Today's health-care headlines.
Alison Southwick owns shares of MAKO Surgical. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical, Illumina, Johnson & Johnson, MAKO Surgical, and Pacific Biosciences of California. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Johnson & Johnson
JNJ
$152.41
(0.26%)
$0.40
Medivation, Inc.
MDVN
MAKO Surgical Corp.
MAKO.DL
Stryker
SYK
$393.55
(0.81%)
$3.15
Roche Holding AG
RHHBY
$40.91
(-0.66%)
$0.27
Hansen Medical, Inc.
HNSN
Alexion Pharmaceuticals
ALXN
Clovis Oncology
CLVS
BioMarin Pharmaceutical
BMRN
$55.11
(1.87%)
$1.01
Illumina
ILMN
$94.78
(0.66%)
$0.62
Pacific Biosciences Of California
PACB
$1.29
(%)
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Which Stock Will Dominate the Weight Management Market Through 2030?
3 No-Brainer Stocks to Buy for Under $100 Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.